| Entry |
|
|---|
| Name |
Erdafitinib (JAN/USAN/INN);
Balversa (TN) |
|---|
| Product |
|
|---|
| Formula |
C25H30N6O2
|
|---|
| Exact mass |
446.243
|
|---|
| Mol weight |
446.5447
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03208 FGFR inhibitor
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
Transporter substrate
DG01665 ABCB1 substrate
Transporter inhibitor
DG01622 ABCB1 inhibitor
DG02863 SLC22A2 inhibitor
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Disease |
Urothelial carcinoma (FGFR3 or FGFR2 genetic alterations) [DS: H00022] |
|---|
| Comment |
Treatment of cancer
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP2C9 [HSA: 1559], CYP3A4 [HSA: 1576]
Transporter: ABCB1 [HSA: 5243]
|
|---|
| Interaction |
Transporter inhibition: ABCB1 [HSA: 5243], SLC22A2 [HSA: 6582]
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
L01EN01 Erdafitinib
D10927 Erdafitinib (JAN/USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Erdafitinib
D10927 Erdafitinib (JAN/USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
DG03208 FGFR inhibitor
D10927 Erdafitinib
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
D10927 Erdafitinib
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D10927 Erdafitinib
Transporter substrate
DG01665 ABCB1 substrate
D10927 Erdafitinib
Transporter inhibitor
DG01622 ABCB1 inhibitor
D10927 Erdafitinib
DG02863 SLC22A2 inhibitor
D10927 Erdafitinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
FGFR family
FGFR2* (CD332) [HSA_VAR:2263v2]
D10927 Erdafitinib (JAN/USAN/INN) <US>
FGFR3* (CD333) [HSA_VAR:2261v2]
D10927 Erdafitinib (JAN/USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10927
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10927
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10927
Drug transporters
D10927
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D10927
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 33
1 C8y C 9.7300 -15.3300
2 C8y C 9.7300 -16.7300
3 C8x C 10.9200 -17.4300
4 C8x C 12.1800 -16.7300
5 C8y C 12.1800 -15.3300
6 C8x C 10.9200 -14.6300
7 N5x N 8.5400 -14.6300
8 C8y C 7.2800 -15.3300
9 C8x C 7.2800 -16.7300
10 N5x N 8.5400 -17.4300
11 C8y C 6.0900 -14.6300
12 C8x C 5.9500 -13.2300
13 N5x N 4.5500 -12.9500
14 N4y N 3.8500 -14.1400
15 C8x C 4.8300 -15.1900
16 C1a C 2.4500 -14.2800
17 N1c N 13.3700 -14.6300
18 C1b C 14.6300 -15.3300
19 C1b C 15.8200 -14.6300
20 N1b N 17.0100 -15.3300
21 C1c C 18.2700 -14.6300
22 C1a C 19.4600 -15.3300
23 C8y C 13.3700 -13.2300
24 C8y C 12.1800 -11.1300
25 C8x C 12.1800 -12.5300
26 C8x C 14.6300 -12.5300
27 C8y C 14.6300 -11.1300
28 C8x C 13.3700 -10.4300
29 O2a O 10.9647 -10.4349
30 O2a O 15.8366 -10.4200
31 C1a C 17.0463 -11.1053
32 C1a C 9.7763 -11.1277
33 C1a C 18.2872 -13.2301
BOND 36
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 1 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 2 10 1
12 8 11 1
13 11 12 1
14 12 13 2
15 13 14 1
16 14 15 1
17 11 15 2
18 14 16 1
19 5 17 1
20 17 18 1
21 18 19 1
22 19 20 1
23 20 21 1
24 21 22 1
25 17 23 1
26 24 25 2
27 25 23 1
28 26 27 1
29 27 28 2
30 24 28 1
31 26 23 2
32 24 29 1
33 27 30 1
34 30 31 1
35 29 32 1
36 21 33 1
|
|---|
